Spots Global Cancer Trial Database for liver cell carcinoma
Every month we try and update this database with for liver cell carcinoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| TAE and MWA Combination Therapy in Early-stage Hepatocellular Carcinoma | NCT02704130 | Hepatocellular ... Hepatoma Liver Cancer, A... Liver Cell Carc... Liver Cell Carc... | Transarterial e... Microwave Ablat... | 18 Years - 75 Years | Wake Forest University Health Sciences | |
| Study of HBV-TCR T Cells (LioCyx-M) as Monotherapy or as Combination With Lenvatinib for HBV-related HCC | NCT05195294 | Hepatocellular ... Liver Cancer, A... Liver Cell Carc... | LioCyx-M Lenvatinib | 18 Years - 75 Years | Lion TCR Pte. Ltd. | |
| A Study of ONCO-DOX in Locally Advanced Hepatocellular Carcinoma | NCT02460991 | Hepatocellular ... Hepatoma Liver Cell Carc... | DEB-TACE Sorafenib | 18 Years - | Boston Scientific Corporation | |
| Regorafenib Plus Pembrolizumab in First Line Systemic Treatment of HCC | NCT03347292 | Carcinoma, Hepa... | Regorafenib(Sti... Pembrolizumab | 18 Years - | Bayer | |
| Immunization With AFP + GM CSF Plasmid Prime and AFP Adenoviral Vector Boost in Patients With Hepatocellular Carcinoma | NCT00669136 | Hepatocellular ... Hepatoma Liver Cancer, A... Liver Cell Carc... Liver Cell Carc... Cancer of Liver Cancer of the L... Cancer, Hepatoc... Hepatic Cancer Hepatic Neoplas... Hepatocellular ... Liver Cancer Neoplasms, Hepa... Neoplasms, Live... | AFP + GM-CSF Pl... | 18 Years - 80 Years | University of Pittsburgh | |
| Exploratory Clinical Study of Apatinib and SHR-1210 in Treating Advanced Hepatocellular Carcinoma or Gastric Cancer | NCT02942329 | Gastric Cancer Hepatocellular ... | apatinib SHR-1210 | 18 Years - 70 Years | The Affiliated Hospital of the Chinese Academy of Military Medical Sciences | |
| Immunization With AFP + GM CSF Plasmid Prime and AFP Adenoviral Vector Boost in Patients With Hepatocellular Carcinoma | NCT00669136 | Hepatocellular ... Hepatoma Liver Cancer, A... Liver Cell Carc... Liver Cell Carc... Cancer of Liver Cancer of the L... Cancer, Hepatoc... Hepatic Cancer Hepatic Neoplas... Hepatocellular ... Liver Cancer Neoplasms, Hepa... Neoplasms, Live... | AFP + GM-CSF Pl... | 18 Years - 80 Years | University of Pittsburgh | |
| Exploratory Clinical Study of Apatinib and SHR-1210 in Treating Advanced Hepatocellular Carcinoma or Gastric Cancer | NCT02942329 | Gastric Cancer Hepatocellular ... | apatinib SHR-1210 | 18 Years - 70 Years | The Affiliated Hospital of the Chinese Academy of Military Medical Sciences | |
| Tislelizumab Consolidation After Liver-Directed Therapy for Hepatocellular Carcinoma | NCT05366829 | Carcinoma, Hepa... Liver Cell Carc... | Tislelizumab | 18 Years - | Rutgers, The State University of New Jersey | |
| Tislelizumab Consolidation After Liver-Directed Therapy for Hepatocellular Carcinoma | NCT05366829 | Carcinoma, Hepa... Liver Cell Carc... | Tislelizumab | 18 Years - | Rutgers, The State University of New Jersey | |
| A Study of Relatlimab in Combination With Nivolumab in Participants With Advanced Liver Cancer Who Have Never Been Treated With Immuno-oncology Therapy After Prior Treatment With Tyrosine Kinase Inhibitors | NCT04567615 | Hepatocellular ... Hepatoma Liver Cancer, A... Liver Cell Carc... Liver Cell Carc... | Nivolumab Relatlimab | 18 Years - | Bristol-Myers Squibb | |
| Regorafenib Plus Pembrolizumab in First Line Systemic Treatment of HCC | NCT03347292 | Carcinoma, Hepa... | Regorafenib(Sti... Pembrolizumab | 18 Years - | Bayer | |
| Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in Autologous T Cells for Solid Tumors | NCT05103631 | Liver Cell Carc... Solid Tumor Wilms Tumor Malignant Rhabd... Yolk Sac Tumor Rhabdomyosarcom... Liposarcoma Embryonal Sarco... | CATCH T cells | 18 Years - | Baylor College of Medicine | |
| Regorafenib-pembrolizumab vs. TACE/TARE in Intermediate Stage HCC Beyond Up-to-7 | NCT04777851 | Carcinoma, Hepa... | Regorafenib in ... Loco-regional t... | 18 Years - | Translational Research in Oncology | |
| Assessment of Novel MRI Quantification Free Breathing Technique in Evaluation of Liver Lesions | NCT02095678 | Hepatocellular ... | liver biopsy free-breathing ... | 18 Years - 100 Years | Case Comprehensive Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
